AI and Rare Diseases ── 2026-11-16
New papers on rare diseases (other than neurological and cancer) and AI, collected from journal feeds, PubMed (searched across all journals) and OpenAlex (a public index used instead of Google Scholar), judged by Jev (an AI that makes language judgements): original research, AI central, which of 8 disease groups, treatment or trials, and then ranked by importance up to a daily limit. Journals are not filtered by impact factor; each paper shows its journal's IF-equivalent (OpenAlex two-year mean citedness) and the date of that value. Each entry shows the full original abstract.
Read by disease: Platforms(1) · Inborn errors of metabolism(0) · Genetic syndromes(0) · Rare blood disorders(1) · Immune and connective tissue(0) · Heart and lung(0) · Kidney, liver and gut(0) · Skin and bone(0)
Rare-disease diagnosis and drug discovery platforms and AI
- Abstract
BACKGROUND: Large language models (LLMs) are increasingly used in medical education, but their ability to analyze pedigree-based genetics problems is not well defined. This exploratory study aimed to compare the accuracy of four consumer LLMs on image-based pedigree questions and to describe the sources of their errors. METHODS: Nine pedigree cases comprising 19 sub-questions were submitted as images on May 18, 2026, to the free consumer versions of ChatGPT (GPT-5.5), Gemini (Gemini 3 Flash), Claude (Claude Sonnet 4.6), and the Microsoft Copilot app, once each in a new chat, without retries or follow-up prompts. The primary measure was accuracy, defined as the number and percentage of sub-questions answered correctly against a predefined answer key reviewed by a medical geneticist. Item-level scores were re-checked during revision using uniform rules. Incorrect answers were retrospectively classified as perception/structure, reasoning/knowledge, mixed or indeterminate errors, or as reported image-access failures. RESULTS: ChatGPT and Claude each answered 14 of 19 sub-questions correctly (73.7%), Copilot 11 (57.9%), and Gemini three (15.8%). Twelve of Gemini's 16 incorrect answers followed its report that it could not see or load the image. Claude's errors in the double-cousin pedigrees reflected misreading of the mating lines, whereas ChatGPT's mainly involved assigning the degree of relationship. In the single atypical pedigree (dominantly inherited hemoglobin S-Oman), no model identified the variant; Claude described dominant features but attributed them to pseudodominance because sickle cell disease is recessive. CONCLUSIONS: In this small, single-attempt task set without statistical comparison, consumer LLMs showed variable accuracy, and errors arose both from misreading pedigrees and from misapplying genetic principles. These results do not establish a ranking of the models or an educational benefit. Consumer AI assistants should complement, not replace, formal instruction and expert supervision in medical genetics.
Journal IF-equivalent: 1.9 (OpenAlex 2-year mean citedness, value as of 2026-11-15, retrieved 2026-11-16; not the official Clarivate IF)Reference: Abduljabbar SS, Alqarni M, Habara A. Consumer Artificial Intelligence for Pedigree Analysis: A Comparative Study in Medical Genetics. Cureus. 2026 Oct 15 [Epub ahead of print]. doi:10.7759/cureus.117953. PMID: 43034519.Checked: Abstract only
Inborn errors of metabolism: treatment, trials and AI
No new qualifying paper for this issue.
Genetic syndromes and paediatric rare diseases: treatment, trials and AI
No new qualifying paper for this issue.
Rare blood disorders: treatment, trials and AI
- Abstract
BACKGROUND: Early detection and management of joint bleeding are critical for preventing long-term joint damage in people with hemophilia. However, current practices often require healthcare professionals to assess bleeding, limiting patient autonomy and potentially leading to delayed or unnecessary treatment. Current literature primarily focuses on clinical protocols for ultrasound (US) imaging but lacks annotation protocols tailored for training artificial intelligence (AI) systems. OBJECTIVES: To propose a structured annotation protocol to support the development of an AI-driven, ultraportable US system that enables people with hemophilia to perform self-guided scans of their joints, focusing specifically on the posterior recess of the elbow, anterior subquadricipital recess of the knee, and anterior recess of the ankle. METHODS: The annotation protocol defines eight criteria to assess the appropriateness of US images and five levels for region-of-interest clarity. A pool of six readers rated US videos of elbows, knees, and ankles from 100 healthy subjects, and their annotations were analyzed using the intraclass correlation coefficient (ICC). RESULTS: The application of the proposed protocol demonstrates moderate to good agreement based on the ICC when assessing the reliability of single ratings from individual readers (ICC(2,1) = 0.7643), with the knee exhibiting the highest reliability. When considering average ratings across multiple readers, we observe overall excellent reliability, with an ICC of 0.9075. CONCLUSION: This annotation protocol supports the development of future AI-guided image-acquisition systems for joint self-scanning, marking a significant step toward at-home joint assessment for people with hemophilia. Future research should address the evaluation of the AI guidance system, patient-performed scanning, and diagnostic accuracy for hemarthrosis.
Journal IF-equivalent: 0.8 (OpenAlex 2-year mean citedness, value as of 2026-11-15, retrieved 2026-11-16; not the official Clarivate IF)Reference: Michelsanti D, Teimouri N, Heindl A, Strike K, Gualtierotti R, Doria AS, et al. Enabling artificial intelligence-driven blind joint ultrasound self-scans in hemophilia: an annotation protocol. Res Pract Thromb Haemost. 2026 Oct;10(7):107019. doi:10.1016/j.rpth.2026.107019. PMID: 43031860.Checked: Abstract only
See all 1 Rare blood disorders papers →
Autoinflammatory, immunodeficiency and rare connective-tissue diseases: treatment, trials and AI
No new qualifying paper for this issue.
Rare cardiovascular and respiratory diseases: treatment, trials and AI
No new qualifying paper for this issue.
Rare kidney, liver and gastrointestinal diseases: treatment, trials and AI
No new qualifying paper for this issue.
Rare skin and bone diseases: treatment, trials and AI
No new qualifying paper for this issue.